Dipyridamole

双嘧达莫

Report date: 2026/04/23 20:00:25
NME

Base Information

Drug NameDipyridamole
Drug Alias NameDipiridamol双嘧哌胺醇dipyridamole双密达莫dipyridamolum +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action3',5'-cyclic phosphodiesterase inhibitors
Targets3',5'-cyclic phosphodiesterase
Therapy Area/IndicationsRejection of renal transplantationCoronavirus Disease 2019 (COVID-19)Hypophosphatemia +[13] 
Global Approved IndicationsThromboembolismMyocardial InfarctionAngina Pectoris +[5] 
Approved Indications in ChinaThromboembolism
Original Approved Country/TerritoryJapan
Original Approved Date1960/05/16
Country/TerritoryCanadaUnited StatesUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesFirst Affiliated Hospital Of Chongqing Medical UniversityStanford UniversityBoehringer Ingelheim Corp +[5] 
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. KgUniversity Of MichiganAriel University +[5] 
Active IndicationsRejection of renal transplantationHypophosphatemiaThromboembolism +[8] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Dry Eye SyndromesPterygium +[5] 

Other Information

ATC CodeB01AC07
Related LinksWikipediaDrugBankKEGG